Analysts Have Conflicting Sentiments on These Healthcare Companies: Haemonetics (HAE) and Ocular Therapeutix (OCUL)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Haemonetics (HAE – Research Report) and Ocular Therapeutix (OCUL – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Haemonetics (HAE)
In a report released today, Michael Matson from Needham maintained a Hold rating on Haemonetics. The company’s shares closed last Thursday at $65.82.
According to TipRanks.com, Matson is a 3-star analyst with an average return of
Currently, the analyst consensus on Haemonetics is a Moderate Buy with an average price target of $88.86, a 36.7% upside from current levels. In a report issued on January 21, Bank of America Securities also reiterated a Hold rating on the stock with a $90.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Ocular Therapeutix (OCUL)
In a report released today, Serge Belanger from Needham maintained a Buy rating on Ocular Therapeutix, with a price target of $20.00. The company’s shares closed last Thursday at $9.15.
According to TipRanks.com, Belanger is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ocular Therapeutix with a $23.43 average price target, which is a 164.7% upside from current levels. In a report issued on January 21, Piper Sandler also maintained a Buy rating on the stock with a $31.00 price target.
